Fascioliasis is a parasitic infection caused by disease transmitted from cattle or sheep through food. This disease is commonly transmitted by consuming aquatic plants like watercress or salad vegetables to which worm cysts are connected, it is also known as 'common liver fluke'. Fascioliasis is caused by two species of parasitic flatworm or trematodes. Fasciola hepatica and Fasciola gigantica trematodes that cause fascioliasis. The diagnosis of fascioliasis is difficult as the parasites are rarely detectable in the initial phase for 9-11 weeks and patients hardly observe any symptoms during that period.
The recommended medicine by the World Health Organisation(WHO) is the Triclabendazole that is known to treat fascioliasis in most of the endemic areas in the world. The drug is mainly available through Centres for Disease Control or CDC in the U.S.A. However, this drug is available under investigation protocol as preventive chemotherapy, and awaiting FDA approval in a few states, shown resistance in both livestock and humans. Hence fascioliasis treatment with alternative drugs holds unprecedented importance as this neglected tropical disease can drastically affect public health and cause high morbidity.
High occurrences of fascioliasis cases, global health challenges in controlling food-borne infections, awareness and participation from governing authorities to fight fascioliasis are the global market drivers. The outburst of fascioliasis in wetlands and cattle rearing regions like Vietnam, Egypt, Peru and Bolivia that require hospitalized treatments especially in young children is a major factor causing global fascioliasis treatment market growth. The trudge in research and development of a suitable drug for fascioliasis is another factor that is estimated to boost the market in upcoming years. Government aid and support towards drug development by emerging new manufacturers are also causing significant growth in the market.
Factors like appropriate dosage complications, temporary post-treatment side effects and longer treatment cycles are few of the road blockers of the global market.
APAC and Latin America are anticipated to grow at a speedy CAGR due to the rise in liver fluke incidences and prevalent dependency on livestock as a food source. Due to strict sanitization norms in Europe and North America Fascioliasis occurrences are negligible resulting in low growth rate. The rest of the world is estimated to grow at a steady pace.